<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A PRoliferation-Inducing TNF Ligand (APRIL) costimulates B-cell activation </plain></SENT>
<SENT sid="1" pm="."><plain>When overexpressed in mice, APRIL induces B-cell <z:hpo ids='HP_0002664'>neoplasia</z:hpo>, reminiscent of human B-cell <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005526'>lymphoid leukemia</z:hpo> (B-CLL) </plain></SENT>
<SENT sid="2" pm="."><plain>We analyzed APRIL expression in situ in human non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>APRIL up-regulation was only observed in high-grade B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>), and Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>Up-regulation was seen in 46% and 20% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, respectively </plain></SENT>
<SENT sid="5" pm="."><plain>In <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e>, neutrophils, constitutively producing APRIL and infiltrating the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> tissue, were the main cellular source of APRIL </plain></SENT>
<SENT sid="6" pm="."><plain>Rare <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> cases showed a predominance of histiocytes or mesenchymal cells as APRIL source </plain></SENT>
<SENT sid="7" pm="."><plain>APRIL secreted by neutrophils accumulated on <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells via <z:chebi fb="0" ids="37396">proteoglycan</z:chebi> binding </plain></SENT>
<SENT sid="8" pm="."><plain>In addition to <z:chebi fb="0" ids="37396">proteoglycans</z:chebi>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DLBCL</z:e> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells expressed the APRIL signaling receptor, TACI and/or BCMA, indicating that these <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells are fully equipped to respond to APRIL </plain></SENT>
<SENT sid="9" pm="."><plain>A retrospective clinical analysis revealed a significant correlation between high expression of APRIL in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> lesions and decreased overall patient survival rate </plain></SENT>
<SENT sid="10" pm="."><plain>Hence, APRIL produced by inflammatory cells infiltrating <z:hpo ids='HP_0002665'>lymphoma</z:hpo> lesions may increase <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:hpo ids='HP_0000718'>aggressiveness</z:hpo> and affect disease outcome </plain></SENT>
</text></document>